[1]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218-224.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
　Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):218-224.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
点击复制

多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
40
期数:
2016年第3期
页码:
218-224
栏目:
出版日期:
2016-05-25

文章信息/Info

Title:
Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease
作者:
李海峰1;  张晓军2;  张锦明2
1. 330029, 南昌, 江西省肿瘤医院核医学科;
2. 100853, 北京, 中国人民解放军总医院核医学科
Author(s):
Li Haifeng1;  Zhang Xiaojun2;  Zhang Jinming2
1. Department of Nuclear Medicine, Jiang Xi Cancer Hospital, Nanchang 330029, China;
2. Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing 100853, China
关键词:
帕金森病; 放射性药物; 正电子发射断层显像术; 多巴胺转运蛋白; 11C-β-CFT
Keywords:
arkinson disease; Radiopharmaceuticals; Positron-emission tomography; Dopamine transporter; 11C-β-CFT
DOI:
10.3760/cma.j.issn.1673-4114.2016.03.011
摘要:
帕金森病(PD)是全球第二大最常见的神经退行性疾病,与患者年龄、激素水平、生活习惯及基因遗传等相关因素密切相关,且与大脑多巴胺能神经元的结构和功能差异有关。常规的影像学检查在PD的早期发现、预后评估、术前分级等方面存在一些不足。11C-甲基-N-2β-甲基酯-3β-(4-氟-苯基)托烷(11C-β-CFT)是一种多巴胺转运蛋白正电子显像剂,与多巴胺转运体的结合具有高度特异性,同时受患者治疗药物因素的干扰较小,是一种良好的临床诊断类的显像剂。目前,11C-β-CFT已应用于人类神经病学方面疾病的研究,如精神分裂症、PD等,11C-β-CFT PET显像可以评价疾病病理、生理过程,便于临床诊断及监测疾病治疗效果等。笔者就近年来11C-β-CFT PET显像在PD中的应用作一综述。
Abstract:
Parkinson disease(PD) is the second most common neurodegenerative disease. It is known to be associated with age, hormonal imbalance, lifestyle exposures, and genetic factors, as well as the differences between the structure and function of the dopaminergic neurons of the brain. Conventional imaging methods exhibit certain limitations in the early detection, prognostic evaluation, and preoperative grading of PD among patients. 11C-methyl-N-2β-carbomethoxy-3β-(4-fluorophenyl)-tropanel(11C-β-CFT) possesses a high affinity for dopamine transporters(DAT) and rarely interferes with anti-Parkinsonism drugs; therefore, 11C-β-CFT is a favorable PET imaging agent for DAT. 11C-β-CFT is widely used as an imaging agent for the diagnosis of human neurological diseases, including schizophrenia and PD. PET imaging with 11C-β-CFT can assist in evaluating physiological and pathophysiological processes, thereby facilitating the diagnosis and monitoring of therapeutic effects. This review summarizes the current applications of 11C-β-CFT PET in PD diagnosis.

参考文献/References:

[1] Shakeri J, Chaghazardi M, Abdoli N, et al.Disease-related variables and depression among iranian patients with parkinson disease[J/OL].Iran Red Crescent Med J, 2015, 17(10):e30246[2016-01-07].http://ircmj.com/?article_id=30246&page=article.DOI:10.5812/ircmj.30246.
[2] Zanellati MC, Monti V, Barzaghi C, et al.Mitochondrial dysfunction in Parkinson disease:evidence in mutant PARK2 fibroblasts[J/OL].Front Genet, 2015, (6):78[2016-01-07].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356157.DOI:10.3389/fgene.2015.00078.
[3] Schapira AH.Mitochondria in the aetiology and pathogenesis of Parkinson’s disease[J].Lancet Neurol, 2008, 7(1):97-109.DOI:10.1016/S1474-4422(07)70327-7.
[4] Gillies GE, Pienaar IS, Vohra S, et al.Sex differences in Parkinson’s disease[J].Front Neuroendocrinol, 2014, 35(3):370-384.DOI:10.1016/j.yfrne.2014.02.002.
[5] Lubomski M, Rushworth RL, Lee W, et al.A cross-sectional study of clinical management, and provision of health services and their utilisation, by patients with Parkinson’s disease in urban and regional Victoria[J].J Clin Neurosci, 2013, 20(1):102-106.DOI:10.1016/j.jocn.2012.05.015.
[6] Huang TT, Wang HL, Tang GH, et al.Human radiation dose estimation of C-11-CFT using Whole-Body PET[J].Clin Nucl Med, 2012, 37(12):1159-1162.DOI:10.1097/RLU.0b013e318266cd1b.
[7] Watanuki S, Tashiro M, Miyake M, et al.Long-term performance evaluation of positron emission tomography:analysis and proposal of a maintenance protocol for long-term utilization[J].Ann Nucl Med, 2010, 24(6):461-468.DOI:10.1007/s12149-010-0381-y.
[8] Dannals RF, Neumeyer JL, Milius RA, et al.Synthesis of a radiotracer for studying dopamine uptake sites in vivo using PET:2β-carbomethoxy-3β-(4-fluorophenyl)-(N-11C-methyl)tropane([11C]CFT or[11C]WIN-35, 428)[J].J Labelled Comp Radiopharm, 1993, 33(2):147-152.DOI:10.1002/jlcr.2580330209.
[9] 张锦明, 田嘉禾, 郭喆, 等.在线自动化制备多巴胺转运蛋白显像剂11C-β-CFT[J].中华核医学杂志, 2005, 25(3):142-145.DOI:10.3760/cma.j.issn.2095-2848.2005.03.006.Zhang JM, Tian JH, Guo Z, et al.Automated on-line preparation of C-β-CFT, a dopamine transporter imaging agent[J].Chin J Nucl Med, 2005, 25(3):142-145.
[10] Park E, Hwang YM, Lee CN, et al.Differential diagnosis of patients with inconclusive Parkinsonian features using[18F] FP-CIT PET/CT[J].Nucl Med Mol Imaging, 2014, 48(2):106-113.DOI:10.1007/s13139-013-0253-1.
[11] Shen LH, Liao MH, Tseng YC.Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders[J/OL].J Biomed Biotechnol, 2012, 2012:259349[2016-01-07].http://www.hindawi.com/journals/bmri/2012/259349.DOI:10.1155/2012/259349.
[12] Yoder KK, Hutchins GD, Mock BH, et al.Dopamine transporter binding in rat striatum:a comparison of[O-methyl-11C]beta-CFT and[N-methyl-11C]beta-CFT[J].Nucl Med Biol, 2009, 36(1):11-16.DOI:10.1016/j.nucmedbio.2008.10.007.
[13] Morris ED, Babich JW, Alpert NM, et al.Quantification of dopamine transporter density in monkeys by dynamic PET imaging of multiple injections of 11C-CFT[J].Synapse, 1996, 24(3):262-272.DOI:10.1016/j.nucmedbio.2008.10.007.
[14] Cicchetti F, Brownell AL, Williams K, et al.Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging[J].Eur J Neurosci, 2002, 15(6):991-998.DOI:10.1016/j.nucmedbio.2008.10.007.
[15] Kawamura K, Oda K, Ishiwata K.Age-related changes of the[11C]CFT binding to the striatal dopamine transporters in the Fischer 344 rats:a PET study[J].Ann Nucl Med, 2003, 17(3):249-253.
[16] Saiki H, Hayashi T, Takahashi RA.Objective and quantitative evaluation of motor function in a monkey model of Parkinson’s disease[J].J Neurosci Methods, 2010, 190(2):198-204.DOI:10.1016/j.jneumeth.2010.05.009.
[17] Pellegrino D, Cicchetti F, Wang X, et al.Modulation of dopaminergic and glutamatergic brain function:PET studies on parkinsonian rats[J].J Nucl Med, 2007, 48(7):1147-1153.DOI:10.2967/jnumed.106.037796.
[18] Liu L, Zhang W, Gong X, et al.Relation between microPET imaging and rotational behavior in a parkinsonian rat model induced by medial forebrain bundle axotomy[J].Behav Brain Res, 2014, 265:148-154.DOI:10.1016/j.bbr.2014.02.008.
[19] Bjorklund LM, Sanchcz-Pernaute R, Chung S, et al.Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model[J].Proc Natl Acad Sci USA, 2002, 99(4):2344-2349.DOI:10.1073/pnas.022438099.
[20] Rinne JO, Laihinen A, Någren K, et al.PET examination of the monoamine transporter with[11C] β-CIT and[11C] β-CFT in early Parkinson’s disease[J].Synapse, 1995, 21(2):97-103.
[21] Ouchi Y, Kanno T, Okade H, et al.Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson’s disease:a double-tracer positron emission tomography study[J].Ann Neurol, 1999, 46(5):723-731.
[22] Ouchi Y, Kanno T, Okade H, et al.Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson’s disease[J].Brain, 2001, 124(4):784-792.
[23] Rinne JO, Iivanainen M, Metsahonkala L, et al.Striatal dopaminergic system in dopa-responsive dystonia:a multi-tracer PET study shows increased D2 receptors[J].J Neural Transm, 2004, 111(1):59-67.DOI:10.1007/s00702-003-0053-3.
[24] Ouchi Y, Yoshikawa E, Sekine Y, et al.Microglial activation and dopamine terminal loss in early Parkinson’s disease[J].Ann Neurol, 2005, 57(2):168-175.DOI:10.1002/ana.20338.
[25] Guo JF, Xiao B, Liao B, et al.Mutation analysis of parkin, PINK1, DJ-1 and ATP13A2 genes in Chinese patients with autosomal recessive early-onset parkinsonism[J].Mov Disord, 2008, 23(14):2074-2079.DOI:10.1002/mds.22156.
[26] Ouchi Y, Yagi S, Yokokura M, et al.Neuroinflammation in the living brain of Parkinson’s disease[J].Parkinsonism Relat Disord, 2009, 15 Suppl 3:S200-204.DOI:10.1016/S1353-8020(09)70814-4.
[27] Ishibashi K, Ishii K, Oda K, et al.Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum[J].Synapse, 2009, 63(4):282-290.DOI:10.1002/syn.20603.
[28] 林伟, 邬剑军, 郭思思, 等.冻结步态的帕金森病患者多巴胺转运体正电子发射断层显像研究[J].中国临床神经科学, 2015, 23(3):268-273.Lin W, Wu JJ, Guo SS, et al.Dopamine transporter PET imaging in patients with freezing of gait of Parkinson’s disease[J].Chin J Clin Neurosci, 2015, 23(3):268-273.
[29] Oda K, Ishii K, Kimura Y, et al.Three-dimensional projection display of striatum dopamine function measured by PET[J].Nihon Hoshasen Gijutsu Gakkai Zasshi, 2002, 58(12):1573-1578.
[30] 何婷婷, 王瑞民, 陈英茂, 等.多巴胺转运蛋白PET成像诊断帕金森病[J].中国医学影像学杂志, 2008, 16(2):94-97.DOI:10.3969/j.issn.1005-5185.2008.02.004.He TT, Wang RM, Chen YM, et al.PET imaging of dopamine transporter(DAT) in the diagnosis of parkinson’s disease[J].Chinese J Med Imaging, 2008, 16(2):94-97.
[31] 王慧春, 左传涛, 黄喆慜, 等.11C-CFT脑PET显像在早期帕金森病诊断中的临床应用[J].中国临床医学影像杂志, 2010, 21(4):229-232.DOI:10.1007/s00535-009-0101-3.Wang HC, Zuo CT, Huang ZM, et al.Application of 11C-CFT PET in the diagnosis of Parkinson’s disease with early-stage[J].J Chin Clin Med Imaging, 2010, 21(4):229-232.
[32] Yagi S, Yoshikawa E, Futatsubashi MA, et al.Progression from unilateral to bilateral parkinsonism in early Parkinson disease:implication of mesocortical dopamine dysfunction by PET[J].J Nucl Med, 2010, 51(8):1250-1257.DOI:10.2967/jnumed.110.076802.
[33] Ishibashi K, Oda K, Ishiwata K, et al.Comparison of dopamine transporter decline in a patient with Parkinson’s disease and normal aging effect[J].J Neurol Sci, 2014, 339(1/2):207-209.DOI:10.1016/j.jns.2014.01.015.
[34] 冼文彪, 史新冲, 张祥松, 等.[11C] CFT脑多巴胺转运体PET显像对帕金森病诊断和严重程度评估的应用[J].中国神经精神疾病杂志, 2014, 40(8):474-478.DOI:10.3936/j.issn.1002-0152.2014.08.006.Xian WB, Shi XC, Zhang XS, et al.Application of[11C]CFT dopamine transporter PET imaging in the diagnosis and severity assessment of Parkinson disease[J].Chin J Nerv Ment Dis, 2014, 40(8):474-478.
[35] Fukae J, Fukaya C, Oshima H, et al.Successful treatment with bilateral deep brain stimulation of the subthalamic nucleus for benign tremulous parkinsonism[J].Rinsho Shinkeigaku, 2014, 54(6):511-514.DOI:http://doi.org/10.5692/clinicalneurol.54.511.
[36] Kono S, Shirakawa K, Ouchi Y, et al.Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier[J].J Neurol Sci, 2007, 252(2):181-184.DOI:10.1016/j.jns.2006.10.019.
[37] Bohnen NI, Gedela S, Herath PA, et al.Selective hyposmia in Parkinson disease:Association with hippocampal dopamine activity[J].Neurosci Lett, 2008, 447(1):12-16.DOI:10.1016/j.neulet.2008.09.070.
[38] 柴黎明, 杨小丰, 王爽, 等.多巴胺转运体显像剂11C-CFT和18F-CFT及其临床应用进展[J].国际放射医学核医学杂志, 2009, 33(4):232-234.DOI:10.3760/cma.j.issn.1673-4114.2009.04.012.Chai LM, Yang XF, Wang S, et al.Dopamine transporter imaging agent 11C-CFT and 18F-CFT and its clinical application development[J].Int J Radiat Med Nucl Med, 2009, 33(4):232-234.
[39] Antonini A, Benti R, De Notaris R, et al.123I-Ioflupane/SPECT binding to striatal dopamine transporter(DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy[J].Neurol Sci, 2003, 24(3):149-150.
[40] Ahlskog JE, Uitti RJ, O’connor Mk, et al.The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson’s disease[J].Mov Disord, 1999, 14(6):940-946.
[41] 焦方阳, 武猛, 王坚, 等.帕金森病不同亚型患者的多巴胺转运体正电子发射断层显像研究[J].中国临床神经科学, 2015, 23(3):262-267.Jiao FY, Wu M, Wang J, et al.Dopamine transporter PET imaging in patients with different subtypes of Parkinson’s disease[J].Chin J Clin Neurosci, 2015, 23(3):262-267.

相似文献/References:

[1]许靖,李肖红,秦永德,等.帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J].国际放射医学核医学杂志,2016,40(5):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
　Xu Jing,Li Xiaohong,Qin Yongde,et al.Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
[2]甘红梅,乔晋萍,孔爱英,等.正电子放射性显像剂代谢及其研究方法进展[J].国际放射医学核医学杂志,2010,34(2):65.[doi:10.3760/cma.j.issn.1673-4114.2010.02.001]
　GAN Hong-mei,QIAO Jin-ping,KONG Ai-ying,et al.The progress on researching method and metabolism of positron radiopharmaceutical[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):65.[doi:10.3760/cma.j.issn.1673-4114.2010.02.001]
[3]顾涛颖,石洪成.放射性药物治疗肿瘤骨转移性骨痛的作用[J].国际放射医学核医学杂志,2010,34(2):88.[doi:10.3760/cma.j.issn.1673-4114.2010.02.006]
　GU Tao-ying,SHI Hong-cheng.The use of radiopharmaceuticals for metastatic bone pain in cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):88.[doi:10.3760/cma.j.issn.1673-4114.2010.02.006]
[4]周雪,乔晋萍,孔爱英,等.受体结合实验及其在放射性显像剂研究中的应用进展[J].国际放射医学核医学杂志,2010,34(6):321.[doi:10.3760/cma.j.issn.1673-4114,2010.06.001]
　ZHOU Xue,QIAO Jin-ping,KONG Ai-ying,et al.Progress on the application of ligand receptor binding assays in radiopharmaceuticals[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):321.[doi:10.3760/cma.j.issn.1673-4114,2010.06.001]
[5]彭添兴,吴华.18F-氟脱氧葡萄糖以外新型PET肿瘤显像剂[J].国际放射医学核医学杂志,2007,31(1):9.
　PENG Tian-xing,WU Hua.New type PET imaging agent excluding 18F-fluorodeoxyglucose in oncology[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):9.
[6]闫卫红.Raclopride在帕金森病PET中的应用[J].国际放射医学核医学杂志,2005,29(1):27.
　YAN Wei-hong.Application of raclopride PET in Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(3):27.
[7]董爱生,田建明.PET、SPECT及MRS在帕金森病诊断中的应用[J].国际放射医学核医学杂志,2005,29(6):244.
　DONG Ai-sheng,TIAN Jian-ming.The application of PET、SPECT and MRS in Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(3):244.
[8]范我.用于肿瘤治疗的放射性药物[J].国际放射医学核医学杂志,2004,28(1):21.
　FAN Wo.Radiopharmaceuticals for tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(3):21.
[9]谭海波,刘兴党.PET在神经干细胞移植治疗帕金森病研究中的进展[J].国际放射医学核医学杂志,2004,28(6):253.
　TAN Hai-bo,LIU Xing-dang.Progress of PET imaging in the study of neural stem cell transplantation treating Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(3):253.
[10]田季雨.PET在帕金森病病理机制研究中的应用近况[J].国际放射医学核医学杂志,2003,27(2):53.
　TIAN Ji-yu.Recent application of PET in the pathological mechanisms of PD[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(3):53.

备注/Memo

备注/Memo:
收稿日期:2016-01-07
基金项目:军队医疗机构制剂标准提高项目(14ZJZ2101)
通讯作者:张锦明,Email:zhangjm301@163.com
更新日期/Last Update: 1900-01-01